Clinical Trials Browser

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Adenocarcinoma

Oligometastatic Prostate Carcinoma

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Prostatic Neoplasms

Biliary Tract Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Cancer Metastatic to Bone

Carcinoma, Transitional Cell

Prostatic Neoplasms

Prostatic Neoplasms

Stage II Bladder Urothelial Carcinoma AJCC v6 and v7

Prostatic Neoplasms

Prostatic Neoplasms

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Infiltrating Bladder Urothelial Carcinoma

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

Carcinoma, Renal Cell, Wilms Tumor

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

DIVINE

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

A Study of Patients Receiving High-Dose Rate Brachytherapy

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

PROMPT

RROPE

Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

CHAMPION

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

oligo-mets

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

FASTR-2

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors

IPI

Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer